Guberina, Maja http://orcid.org/0000-0003-3218-0539
Sak, Ali
Pöttgen, Christoph
Tinhofer-Keilholz, Ingeborg
Budach, Volker
Balermpas, Panagiotis
Von der Grün, Jens
Rödel, Claus Michael
Gkika, Eleni
Grosu, Anca-Ligia
Abdollahi, Amir http://orcid.org/0000-0002-8016-5897
Debus, Jürgen
Belka, Claus
Pigorsch, Steffi
Combs, Stephani E.
Mönnich, David
Zips, Daniel
De-Colle, Chiara
Welz, Stefan
Linge, Annett http://orcid.org/0000-0001-9636-1721
Lohaus, Fabian
Baretton, Gustavo
Gauler, Thomas
Baumann, Michael http://orcid.org/0000-0002-9340-974X
Krause, Mechthild
Schuler, Martin
Bankfalvi, Agnes
Höing, Benedikt
Lang, Stephan
Stuschke, Martin
Article History
Received: 23 June 2019
Revised: 9 May 2020
Accepted: 28 May 2020
First Online: 16 June 2020
Change Date: 30 September 2020
Change Type: Update
Change Details: The original version of this Article contained an error in the spelling of the author Eleni Gkika, which was incorrectly given as Eleni Gikka. As well as the author Stephanie E. Combs, this was incorrectly given as Stephanie Combs. Both have now been corrected in the PDF and HTML versions of the Article.
Change Date: 2 October 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Compliance with ethical standards
:
: MG, AS, CP, IT, VB, PB, JVG, CMR, EG, A-LG, AB, BH, SL, AA, JD, CB, SP, SC, AL, FL, GB, TG, MS: all authors declare that they have no conflict of interest. MB: In the past 5 years, MB attended an advisory board meeting of MERCK KGaA (Darmstadt), for which the University of Dresden received a travel grant. He further received funding for his research projects and for educational grants to the University of Dresden by Teutopharma GmbH (2011- 2015), IBA (2016), Bayer AG (2016-2018), Merck KGaA (2014-open), Medipan GmbH (2014-2018). He is on the supervisory board of HI-STEM gGmbH (Heidelberg) for the German Cancer Research Center (DKFZ, Heidelberg) and also member of the supervisory body of the Charité University Hospital, Berlin. As former chair of OncoRay (Dresden) and present CEO and Scientific Chair of the German Cancer Research Center (DKFZ, Heidelberg), he has been or is still responsible for collaborations with a multitude of companies and institutions, worldwide. In this capacity, he discussed potential projects with and has signed/signs contracts for his institute(s) and for the staff for research funding and/or collaborations with industry and academia, worldwide, including but not limited to pharmaceutical corporations like Bayer, Boehringer Ingelheim, Bosch, Roche and other corporations like Siemens, IBA, Varian, Elekta, Bruker and others. In this role, he was/is further responsible for commercial technology transfer activities of his institute(s), including the DKFZ-PSMA617 related patent portfolio [WO2015055318 (A1), ANTIGEN (PSMA)] and similar IP portfolios. He confirms that to the best of his knowledge none of the above funding sources was involved in the preparation of this paper. MS: Research grant was contributed by AstraZeneca in 2019 and 2020. MS confirms that the above mentioned funding source was not involved in the study design or materials used, neither in the collection, analysis, and interpretation of data nor in the writing of the paper. Consultant (compensated): AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Novartis, Roche. Honoraries for CME presentations: Abbvie, Alexion, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Lilly, MSD, Novartis, Pierre Fabre. Research funding to institution: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Novartis. MK: conflict of interest statement. In the past 5 years, MK received funding for her research projects by IBA (2016), Merck KGaA (2014–2018 for preclinical study; 2018–2020 for clinical study), Medipan GmbH (2014–2018), Attomol GmbH (2019–2021), GA Generic Assays GmbH (2019–2021), BTU Cottbus-Senftenberg (2019–2021), Gesellschaft für medizinische und wissenschaftliche genetische Analysen (2019–2021), Lipotype GmbH (2019–2021), PolyAn GmbH (2019–2021). For the present study, MK confirms that none of the above mentioned funding sources were involved in the study design or materials used, nor in the collection, analysis and interpretation of data nor in the writing of the paper.
: Statement on ethics approval and consent by the ethics committee of the Faculty of Medicine, University Duisburg-Essen, University Hospital Essen (Prof. Havers, Prof. Schara) is available: registration number 14-5816-BO.